Open AccessBacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an In Vitro Pharmacokinetic/Pharmacodynamic Model
Author(s) -
Razieh Kebriaei,
Katherine L. Lev,
Kyle Stamper,
Susan M. Lehman,
Sandra Morales,
Michael J. Rybak
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01863-20
Subject(s) - bacteriophage , pharmacodynamics , microbiology and biotechnology , antibiotics , pharmacokinetics , staphylococcus aureus , biology , in vivo , in vitro , virology , pharmacology , bacteria , escherichia coli , genetics , gene
This study aimed to test the efficacy of bacteriophage-antibiotic combinations (BACs) in vitro in 24-h time-kill settings and in ex vivo simulated endocardial vegetation (SEV) pharmacokinetic/pharmacodynamic models for 96 h. BACs prevented the development of bacteriophage resistance, while some bacteriophage resistance emerged in bacteriophage-alone treatments. In addition, BACs resulted in an enhancement of bacterial eradication in SEV models. Our findings support the potential activity of BAC therapy for combating serious methicillin-resistant Staphylococcus aureus (MRSA) infections.